Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) and PainReform (NASDAQ:PRFX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.
Valuation and Earnings
This table compares Larimar Therapeutics and PainReform”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Larimar Therapeutics | N/A | N/A | -$165.67 million | ($2.21) | -1.80 |
| PainReform | $20,000.00 | 38.80 | -$5.02 million | ($736.66) | 0.00 |
Analyst Ratings
This is a summary of recent ratings and price targets for Larimar Therapeutics and PainReform, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Larimar Therapeutics | 1 | 0 | 6 | 3 | 3.10 |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
Larimar Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 315.62%. Given Larimar Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Larimar Therapeutics is more favorable than PainReform.
Profitability
This table compares Larimar Therapeutics and PainReform’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Larimar Therapeutics | N/A | -137.70% | -101.43% |
| PainReform | N/A | N/A | N/A |
Risk & Volatility
Larimar Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Insider & Institutional Ownership
91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Larimar Therapeutics beats PainReform on 7 of the 13 factors compared between the two stocks.
About Larimar Therapeutics
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
